UNSPSC 51434104: Pentamethonium

This classification denotes a nicotinic antagonist with the molecular formula C11H28N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 521DS2D2HB, chemically known as 1,5-pentanediaminium, n,n,n,n,n,n-hexamethyl-, dibromide (9ci) but generally known as pentamethonium bromide, which bears US NIH Compound Identifier 10919. European Medicines Agency schedules Pentamethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09681MIG. The term PENTAMETHONIUM is an International Non-Proprietary Name.

As of Q4 2014, PENTAMETHONIUM remains the US FDA Preferred Term for this commodity. Pentamethonium bears US NLM identifiers UMLS ID C0070299 and NCI Concept Code C84044. SMILES: C[N+](C)(C)CCCCC[N+](C)(C)C.

UNSPSC 51434104 Pentamethonium is a Commodity code that in practice captures state and local procurement of emergency medications and pharmaceutical products for public safety and healthcare delivery. Recent solicitations show state and local governments purchasing emergency life support drugs, generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles. The City of Tampa Fire Rescue's April 2026 IFB for advanced life support medications—including Labetalol, Epinephrine, Adenosine, and Diltiazem—illustrates the scope: acquisition of specific drug line items with firm pricing, expiration-date warranties, rapid delivery, and OSHA compliance. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances representing multiple state and local members. The Texas Health and Human Services Commission's April 2026 RFI signals emerging interest in direct-to-manufacturer pharmacy contracting outside traditional PBM and GPO channels.

Activity concentrates in Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a broad RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The Tampa IFB (Solicitation 26P00188, due April 8, 2026) carried an estimated contract value of $40,000 and included a 5 percent bid discount for Small Local Business Enterprises. MMCAP's RFP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards effective July 1, 2026. Vendors must maintain cGMP certification, DSCSA compliance, and comprehensive insurance including $5 million commercial general liability coverage. Performance penalties and administrative fees apply; no aggregate contract value for the MMCAP opportunity is disclosed in the solicitation materials.